Phospholipase C-c (PLCc ) has been implicated in tumor cell motility required for invasiveness and metastasis. Diminished tumor dissemination has been demonstrated in xenograft models, but studies in naturally-occurring tumors are lacking, having been limited by the timing of the interventions. Therefore, we generated mice that express a doxycycline (DOX)-inducible dominantnegative fragment of PLCc, PLCz; this approach avoids the in utero lethality caused by the absence of PLCc. As we targeted two de novo-occurring carcinomas of the mammary (MMTV-driven polyoma middle T antigen model, PyVmT) and prostate (TRAMP model) glands, we limited expression to these epithelial cells by driving DOX transactivator from the prostatein C3 promoter. This avoids the confounding variable of potentially abrogating motility in stromal and endothelial cells. These mice developed normally in the presence of DOX, except for limited mammary development if treated before 6 weeks and immaturity of the prostate gland if treated before 2 weeks of age. DOX-mediated induction of PLCz from age 8 to 16 weeks in PyVmT mice decreased the number of lung metastases by >10-fold (Po0.06) without a detectable effect on in situ tumor cell proliferation or tumor size. Lung metastases were also significantly decreased in the TRAMP model in which the mice expressed the PLCz fragment (Po0.05). DOX treatment itself had no effect on tumor size or metastasis in control mice, nor did it affect tumor dissemination in nontransgenic littermates. In conclusion, abrogation of the PLCc signaling pathway can limit the metastatic potential of carcinomas.
Introduction
Cancer morbidity and mortality results mainly from invasion and dissemination of the primary tumor. This spread of the tumor requires cell proliferation, motility and survival in an ectopic environment Fidler, 2003; Wang et al., 2005) . Inhibition of any one of these steps would stop tumor dissemination. However, therapies aimed at cell proliferation and survival have been limited by toxicity as these properties are common to normal homeostatic mechanisms. On the other hand, the induced motility noted during tumor invasion and metastasis appears to be a re-iteration of that noted during organogenesis and regenerative wound repair (Wells, 2000) , and not molecularly analogous to the motility extant during homeostasis. This offers a novel avenue for intervention against tumor spread that could have minimal toxicity. Key molecular switches have been identified during induced cell migration of tumor cells (Wells, 2000; Ridley et al., 2003) . These are downstream of growth factor receptors activated by autocrine and paracrine signals. These switches include phospholipase C-g (PLCg), activation of which lies upstream of cytoskeletal reorganization. PLCg appears to be at a convergence point of various signaling pathways leading to spreading and motility, including those from adhesion receptors, and as such offers an opportunity for differential abrogation of multiple yet distinct signaling events (Kassis et al., 1999; Jones et al., 2005) . In previous studies, we tested whether PLCg signaling contributes to tumor invasion indirectly through an examination of EGF receptor-mediated invasiveness. We engineered EGFR constructs that were fully mitogenic, but either activated PLCg (WT) or did not (c'973) in DU-145 androgen-independent human prostate cancer cells. The cells expressing the WT EGFR were significantly more invasive through Matrigel and xenograft models (Xie et al., 1995; Turner et al., 1997) . When this cascade was intervened at the level of PLCg using pharmacological inhibitors (U73122) or a dominant-negative fragment (PLCz), tumor invasiveness and dissemination was inhibited in xenograft models, but tumor growth was unaffected. Subsequent studies confirmed the applicability of PLCg signaling of tumor cell invasiveness in other prostate tumor cells as well as those derived from breast, bladder and oral mucosa (Kassis et al., 1999; Price et al., 1999; Dittman et al., 2002; Thomas et al., 2002) .
Although these published reports provide a 'proof-ofconcept' that PLCg signaling can be targeted to limit carcinoma invasion (Mouneimne et al., 2004) , in vivo experiments have been lacking to support this clinically relevant hypothesis that such inhibition limits tumor metastasis. Therefore, we have developed a doubletransgenic model of oncogene-induced mammary or prostate carcinoma in which PLCg can be conditionally regulated, thus avoiding tumor suppressive effects during early phases of transformation. By limiting the expression of a dominant-negative PLCg fragment (PLCz) to the epithelial cells of the mammary and prostate glands (Guy et al., 1992; Tehranian et al., 1996) , we also avoid any questions as to limiting stromal responsiveness or angiogenesis needed for metastases to become macroscopic. We tested the hypothesis in spontaneous tumor models of mammary and prostate carcinomas. In these models, induction of the dominantnegative fragment PLCz clearly decreased the number of metastases to the lung. These results not only support tumor cell motility as a rate-limiting step in metastasis but also are the first to limit dissemination of in situ de novo-occurring tumors by inhibiting PLCg-mediated motility.
Results
Expression of the DOX-inducible PLCz transgene is restricted to mammary and prostate epithelia A constitutively active PLCz transgene under the control of the C3(1) prostatein promoter (Guy et al., 1992; Tehranian et al., 1996) was constructed. The rat C3(1) prostatein promoter drives the expression of the reverse tetracycline transactivator (rTetR-VP16) that binds to TRE (tetracycline response element) and activates the transcription of PLCz in the presence of doxycycline (DOX) (Figure 1a) . We chose to utilize expression of a dominant-negative rather than an inducible excision/deletion situation for two reasons, one being that low level leakage of expression would lead to inadvertent deletion but not competition, and the second being the ability to revert to a PLCg-positive state by withdrawal of DOX. The predicted 800 bp PCR product was amplified from positive PLCz transgene founders (Figure 1b) .
The expression of the transgene was confirmed by immunoblot analysis of protein from tissues of mice using a polyclonal anti-PLCg antiserum. We treated mice between 4 and 8 weeks of age with DOX to determine if PLCz expression was inducible and in which tissues it would be expressed. After 1 week of DOX treatment, PLCz was found only in the prostate and mammary glands of transgenic animals and not in the wild-type littermates. The 51 kDa PLCz band was not detected in mice in the absence of DOX treatment, nor was it found in nontransgenic mice in the presence of DOX (Figure 2a ). We did not detect PLCz in the ventral prostate and seminal vesicles, consistent with reports of C3(1) being expressed only in the dorsal prostate ( Figure 2b ; Claessens et al., 1989; Maroulakou et al., 1994; Tehranian et al., 1996) .
The persistent expression of PLCz depended on continued treatment with DOX, as removal of the DOX-laced drinking water resulted in dramatically reduced PLCz expression after 2 weeks (Figure 2c ). For both the induction and reversion experiments, we probed the protein rather than mRNA, as protein processing and stability might be extended and thus alter the kinetics of biological response. As abrogation of signaling by dominant-negative constructs requires excess expression, we confirmed that PLCz expression was significantly higher than that of endogenous PLCg, seen at low levels at 130 kDa (Figure 2a) . These results (1) transgenic (2) transgenic (3) transgenic (4) transgenic (5) wild-type (1) wild-type (2) CMV minimal promoter C3(1) Promoter Figure 1 Generation of PLCz-expressing mice. The pC3(1)tPLCz bicistronic construct (a) contains the reverse tet repressor driven by the breast and prostate specific promoter, C3(1), that binds to the TRE (tetracycline response element) in the presence of doxycycline (DOX). VP-16 transcriptional activation domain of herpes simplex virus enhances expression of the downstream PLCz. Thus, PLCz expression is expressed only on DOX induction in a tissue-specific manner. To detect transmission of the pC3(1)tPLCz construct, 1 mg of genomic DNA from a tail of each transgenic or wild-type mouse was used to perform the PCR analysis. 10 pg of transgene fragment from pTGC3(1) was used as template for the positive control and there is no template with the negative control. (b) The arrow head indicates the 0.8 kb PCR products from the transgene. strongly indicate that the C3(1) promoter is able to induce the transgene expression in a tissue-specific and regulatable manner in the mammary and prostate gland of transgenic mice.
Induction of PLCz inhibits invasiveness of the primary tumor and metastatic tumor formation To determine whether a PLCg-mediated motilityassociated signaling pathway is associated with tumor cell dissemination, the pC3(1)tPLCz transgene founders were crossed with MMTV-PyVmT and TRAMP mice to generate double transgenic MMTV-PyVmTPLCz (PyVmT-PLCz) mice and TRAMP-PLCz mice. MMTV-PymT transgenic mice develop mammary tumors with an average latency of 53 days and form lung metastases with 100% penetrance by 100 days of age (Muraoka et al., 2002) . TRAMP transgenic mice develop prostate tumors with an average latency of 84 days and form lung metastases with 95% penetrance by 24 weeks of age (Gingrich et al., 1997) .
In the absence of DOX, tumors arose with similar latencies to MMTV-PyVmT and TRAMP mice. Because the average tumor latency for the PyV-PLCz mice was B8 weeks, DOX was administered no earlier than 9 weeks to allow both the mammary gland to form (Supplementary Figure 1) and primary tumor formation to occur. In TRAMP mice, tumor formation began soon after birth, so DOX was administered beginning immediately after weaning. The majority of DOXtreated PyVmT-PLCz and TRAMP-PLCz mice exhibited signs of high carcinoma load-related distress at 16 weeks and 24 weeks, respectively, and were killed.
The primary tumors in the prostate of the TRAMPPLCz mice were scored for invasiveness after 24 weeks of DOX treatment. The TRAMP-PLCz mice displayed a significantly decreased invasiveness score of the tumor into the prostate parenchyma when compared with the untreated mice, while the no-insert controls and untreated controls remained indistinguishable (Table 1A) . When comparing the invasiveness score of the DOX-treated PLCz-positive mice with the DOXtreated transgene-absent control mice, the DOX-treated PLCz positive mice displayed a significantly decreased invasiveness score of the tumor into the prostate parenchyma that was significantly lower than the DOX-treated transgene-absent mice (Po0.02).
Lung metastases were counted at 24 weeks of age in the TRAMP mice and 16 weeks of age in the PyVmTPLCz mice, based on literature-reported development and pilot experiments. In the TRAMP-PLCz mice, after less than 24 weeks of DOX treatment, the TRAMPPLCz mice displayed a significantly decreased number of lung metastases when compared with TRAMP-PLCz mice without DOX treatment, while the controls, as above, remained indistinguishable (Table 1B) .
To determine if this reduced metastasis also held in other tumors, we checked the mammary tumor spontaneously arising in the PyVmT mice. After 8 weeks of DOX treatment, the PyVmT-PLCz mice displayed a Fisher's exact test was used to generate P-values to determine whether induction of PLCz had a significant influence on the extent of lung metastases. A, TRAMP and TRAMP/PLCz mice were scored for invasiveness of the primary prostate tumors. The TRAMP mice expressing the PLCz trangene had a significant reduction in the invasiveness of the primary tumor (P ¼ 0.02). B, TRAMP and TRAMP/PLCz mice were scored for the extent of the lung metastases. The TRAMP mice expressing the PLCz transgene had a significant decrease in the extent of lung metastasis (P ¼ 0.06). C, PyVmT and PyVmT/PLCz mice were scored as in (B). The PyVmT mice expressing the PLCz transgene had a significant decrease in the extent of lung metastasis (P ¼ 0.03).
significantly decreased number of lung metastases when compared with PyVmT-PLCz mice without DOX treatment (Po0.02), whereas the 'no insert' controls and positive insert/no treatment mice remained statistically indistinguishable (Table 1C ; Figures 3 and 4a) . While the lung metastases did trend to be smaller in the PLCzexpressing inductants, the trend was not statistically significant. Primary mammary tumors from DOX-treated PyVmT and PyVmT-PLCz mice had no differences in tumor volume owing to DOX induction (Figure 4b ). The number of lung metastases in PyVmT-PLCz mice not induced to express PLCz by DOX was not different from the number observed in MMTV-PyVmT mice.
Discussion
Tumor invasion, both into adnexia and as the first step in dissemination, has been proposed to be a consequence of dysregulated cell motility (Kassis et al., 2001) . The dissemination of cells from the primary tumor to metastatic sites is limiting for the tumor's progression. Although many of the molecules that regulate or effect cell motility have been investigated (Ridley et al., 2003) , the dysregulation of those same molecular events has yet to be properly characterized in the context of the dissemination and metastatic seeding of de novo arising cancers. The models examined herein, are of spontaneous metastasis of in situ carcinomas that arise secondary to oncogenic activation. We queried whether the dissemination of such tumors can be limited by blocking a key cell motility pathway, that of PLCg.
PLCg signaling is an enticing target to dissect the contributions of induced cell motility to tumor progression, as it distinguishes the cell motility response from that of proliferation (Chen et al., 1996) . Obviously, any intervention that also prevents proliferation would be falsely scored as metastasis suppressing, as metastasis requires subsequent proliferation. Despite the extensive investigations on motility in culture systems and confirmation in xenograft models, experimental evidence is lacking as to the relative or specific contributions of motility on the metastatic dissemination of de novo-occurring cancer cells. This is due to the pleiotropic nature of the signals during tumor progression, such as the autocrine stimulatory loops activating growth factor receptors that drive both motility and proliferation. For instance, current molecularly-targeted therapies inhibit signaling from the EGFR family members HER2 (erbB2) and HER1 (EGFR, erbB1). Both of these receptors initiate and sustain proliferation and migration in breast and prostate carcinoma cells. Thus, while these inhibitors limit dissemination, whether growth factor-enhanced motility underlies metastasis remains unproven. Abrogation of PLCg signaling by pharmacological or genetic means eliminates motility but not mitogenesis induced by EGFR, HER2 (Chen et al., 1994a, b) and other growth factor receptors (Reddy et al., 1996) . By targeting this convergent downstream effector molecule, we defined a role for growth factorinduced cell motility in the dissemination of primary breast and prostate cancer in vivo.
In this study, we conditionally expressed a dominantnegative fragment of PLCg in the mammary and prostate epithelium of TRAMP and MMTV-PyVmT. This conditional, post-natal expression was required as constitutive ablation of PLCg is embryonic lethal (Ji et al., 1998b) . Furthermore, by limiting expression to the target epithelial cells, we avoid issues of altering the microenvironment of the primary and metastatic tumor sites, as well as affecting tumor-associated angiogenesis (Bodnar et al., 2006) . We chose a reversible, inducible system rather than conditional gene deletion (i.e. CreLox) for the flexibility provided by the ability to revert to a functional phenotype (see Supplementary data).
Expression of the dominant-negative PLCz construct during prenatal and immediate post-natal periods retarded organogenesis specific to the prostate and mammary epithelium (Supplementary Figures 1 and  3) . This was reversible upon DOX withdrawal, validating our strategy and demonstrating that low-level leakiness of the tetracycline-on system was not consequential as a dominant-negative is only effective when in stoichiometric excess.
To study the role of PLCg signaling in metastasis, we allowed organogenesis and maturation to proceed, and spontaneous tumorigenesis to be initiated by the transgenic oncogenes. Forcing expression of PLCz limited the metastases from both the breast and prostate carcinomas; the lungs were chosen for ease and reproducibility of quantitation, though similarly decreased metastasis was noted in other internal organs (data not shown). The one caveat is that overexpression of a phosphotyrosine-binding moiety, such as PLCz, may interfere with downstream signaling cascades in addition to the specific one targeted, in this case PLCg. We were not able to demonstrate equivalent activation of other non-PLCg cascades in vivo owing to technical challenges. However, in prostate tumor cells lines expressing PLCz, we did not note diminished basal or EGFR-triggered cell proliferation nor size of tumor at the primary site, as compared to the cell line without the PLCz transgene (Turner et al., 1997) . Furthermore, this decrease in number and size of metastases herein appeared not due to slower tumor growth as the primary tumor sizes were unaffected by PLCz expression. These data confirm that cancer cell invasiveness is a determining factor of tumor progression in vivo.
These studies confirm that PLCg function is necessary for tumor cell dissemination in both breast and prostate cancers. That metastasis was incompletely abrogated is not unexpected, but may be due to several reasons. First, the expression of PLCz does not completely eliminate EGF-induced PIP 2 hydrolysis in vitro (Chen et al., 1994a) and may be similarly incomplete in in vivo systems. Second, some low-level EGF-induced motility is noted in PLCg-1 devoid cells (Ji et al., 1998a) . this is owing to other pathways that regulate motility-associated processes other than protrusion, such as ERK MAP kinase/ m-calpain (Chen et al., 1996; Glading et al., 2000) and PKCd/MLC (Iwabu et al., 2004) , as well some upregulation of PLCg-2 expression. It should also be noted that while the targeted inhibition of PLCg is being discussed as a downstream effector required for EGFR-mediated motility, we cannot be certain that the extracellular trigger for breast and prostate cancer dissemination are the EGFR ligands. EGFR signaling is likely to be the primary trigger as it has been implicated in the transformation, mitogenic and motogenic properties of tumor cells (Carpenter, 2000) . However, it is possible that other growth factors or adhesion receptors are signaling via PLCg (Carpenter and Ji, 1999; Jones et al., 2005) . As PLCg seems to serve as a point of convergence for PDGF, HGF and IGF-1 in addition to EGF in signaling motility (Bornfeldt et al., 1994; Kundra et al., 1994) , expression of PLCz would be expected to diminish cell motility signaled by all of these factors. Furthermore, PLCg has been linked to integrin-related changes that result in cell motility in the context of invading cancer cells (Jones et al., 2005) . The progression of invasive cancers to the morbidity and mortality of metastasis encompasses a series of highly coordinated events, though the literature offers a compelling line of evidence for the motility-related role of PLCg throughout the metastatic process. We have demonstrated here that signaling through PLCg is a necessary and potentially limiting step that may be targeted in a rational intervention. (See Supplementary information).
Materials and methods
All animal experimentations were approved by the Institutional Animal Care and Use Committees respective to where the experiments were carried out, including the University of Pittsburgh, Pittsburgh VAMC, and the University of Alabama at Birmingham.
Generation of double transgenic TRAMP and MMTV-PyVmT with a DOX-inducible PLCz transgene
The reverse tetracycline plasmids (tet-on) PUHD13-6 and PUHD172-1neo were kindly provided by Dr Hermann Bujard (Heidelberg) (Gossen et al., 1995) . The CMV promoter driving the reverse tet repressor (rTetR) of PHUD172-1neo was replaced with rat C3(1) prostatein promoter (kindly provided by Dr Peter Barry, UC Davis (Tehranian et al., 1996) ). The dominant-negative PLCg fragment, PLCz (Homma and Takenawa, 1992; Chen et al., 1994a) , was placed downstream of the TRE with the TATA box from CMV minimal promoter of PUHD13-6. These two DNA fragments containing C3(1)rtetR and TRE-TATA-PLCz were ligated into the pBluescript to create a single bicistronic construct; this was done to increase expression levels (Hofmann et al., 1996) and simplify breeding schemes by physically linking the two halves of the system. The resulting plasmid, pC3(1)tPLCz, was used in microinjection ( Figure 1a) pC3(1)tPLCz was digested with NotI and PstI and electrophoresed through a 0.7% low-melting point agarose gel and purified using Quiax DNA binding beads. Purified DNA was injected into one cell FBV zygotes by the University of Alabama at Birmingham transgenic polyomafacility (Carl Pinkert, Director). Following injection, viable eggs were transferred to the oviducts of pseudopregnant female mice. To identify positives, DNA was extracted from 1-cm section of tails using Quiamp DNA extraction kit (Quiagen). DNA was resuspended with 200 ml of TE (10 mM Tris, 1 mM EDTA pH 8.0). Screening of transgenic mice was by polymerase chain reactions with one pair of oligonucleotides annealed to the PLCz. The PCR was performed on a DNA thermocycler (Ericomp Inc., San Diego, CA, USA) using the following program: 941C for 1 min, 561C for 1 min, and 721C for 1 min. PCR product was analysed by electrophoresis on a 1% agarose gel (Figure 1b) .
The PLCz mice were mated with TRAMP mice, kindly provided by Norman Greenburg (Gingrich et al., 1996) , or MMTV-PyV mice, the gift of Dr WJ Muller (Webster et al., 1998) . Male PLCz mice were mated with female TRAMP mice or female PLCz were mated with male MMTV-PyV mice. The F1 crosses were used for all experiments. The mice lacking the PLCz transgene presented tumors at the expected rates and times.
PLCz expression
To induce expression of the PLCz transgene, DOX was also administered orally in drinking water (2 mg/ml) for varying times before killing the mice. Various tissues from wild type and transgenic mice were sonicated in PBS with protease inhibitors (10 mg/ml leupeptin, 20 mg/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride). The concentration of each sample was determined by measuring the absorbance at 595 nm using Biorad Bradford assay. Lysates of 50 mg were subjected to 10% SDS-PAGE and the resolved proteins were transferred electrophoretically to PVDF membrane. After shaking the blot in TBST with 5% non-fat dry milk (w/v) for 1 h, blot was incubated with the anti-rabbit PLCg antibody (Santa Cruz Biotech, Santa Cruz, CA, USA) at 41C overnight. After incubation with primary antibody, the blot was washed in TBST for 15 min twice and incubated with secondary antibody (anti-rabbit IgG, 2500:1 dilution, Promega, Madison, WI, USA). Protein bands were visualized with NBT and BCIP (Promega).
Histologic and immunohistochemical assessments of mammary and prostate glands For histology, part of mammary gland and dorsal prostate gland were fixed in 10% neutral buffered formalin, processed for paraffin sectioning and stained with hematoxylin and eosin. Paraffin sections were deparaffinized, hydrated, pretreated with 2 N HCl for 20 min at 371C and exposed to 0.01% trypsin at 371C for 3 min, followed by staining using a mouse monoclonal anti-PCNA antibody and biotinylated secondary antibody. 3,3
0 Diaminobenzidine tetrahydrochloride was used as chromogen. Sections were also tested for apoptosis using the Apotag kit (Oncor Inc., Gaithersburg, MD, USA). After hydration, sections were treated with proteinase K (20 mg/ml) and the endogenous hydrogen peroxide was quenched by incubating with 2% hydrogen peroxide in PBS. Terminal deoxytransferase was added to sections followed by incubation with anti-digioxigenin antibody conjugated with HRP. Color detection was accomplished with DAB as Chromogen.
The primary and metastatic tumors were scored for invasion of the parenchyma and were evaluated using a method modified from Eneroth (Jakobsson et al., 1973) . The tumor invasion modes were scored into four histopathologic malignancy grades, given as (score), gross description: (0.5) micrometastasis; (1) well-defined border; (2) cords/Indian files, less well defined border; (3) groups of cells, no distinct border; (4) diffuse growth.
Statistical analyses
Data were categorized into PLCzÀ/No DOX, PLCz þ /No DOX, PLCzÀ/DOX and PLCz þ /DOX groups. Differences in continuous parameters (size, number) were evaluated by Wilcoxon Rank Sum Test using the SAS statistical software package (Cary, NC). Fisher's exact test was used to evaluate the significance of differences in the parameters. All Ps are represented by one-tailed tests (Kassis et al., 1999) and were deemed statistically significant at Po0.10; although levels of statistical differences are provided.
